Welcome to our dedicated page for Repare Therapeutics SEC filings (Ticker: RPTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Repare Therapeutics Inc. (RPTX) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including Form 8-K reports that describe material events and corporate transactions. Repare’s common shares are registered under Section 12(b) of the Securities Exchange Act of 1934 and trade on The Nasdaq Stock Market LLC under the symbol RPTX, as reflected in its filings. These documents offer insight into the company’s precision oncology business, strategic agreements, and planned change in corporate structure.
Recent Form 8-K filings detail key developments such as the arrangement agreement with XenoTherapeutics, Inc. and Xeno Acquisition Corp., under which Xeno will acquire all issued and outstanding common shares of Repare through a court-approved plan of arrangement under the Business Corporations Act (Québec). The November 17, 2025 8-K describes the transaction terms, including a cash amount per share based on closing net cash and the issuance of non-transferable contingent value rights (CVRs) that entitle holders to potential future cash payments tied to specified receivables, partnerships with Bristol-Myers Squibb, Debiopharm and DCx Biotherapeutics, and licensing or disposition of product candidates and intellectual property.
Other 8-K filings referenced in 2025 address topics such as quarterly financial results, executive compensation and severance arrangements, and scientific and clinical communications, including the availability of abstracts related to the Phase 1 LIONS trial of RP-1664. These filings complement Repare’s press releases by providing formal regulatory descriptions of material agreements, voting and support arrangements with directors and officers, and conditions to closing for the Xeno transaction.
On Stock Titan, users can review these SEC filings alongside AI-powered summaries that explain complex sections, highlight the practical implications of items such as CVR structures, termination fees or voting thresholds, and help interpret how agreements and disclosures relate to Repare’s precision oncology programs. The page also serves as a reference point for tracking Repare’s transition from a Nasdaq-listed issuer toward becoming a privately held company, as described in its public filings and transaction announcements.
Repare Therapeutics Inc. saw its largest shareholders cashed out in a merger. Investment funds affiliated with BVF Partners, including Biotechnology Value Fund, Biotechnology Value Fund II and Biotechnology Value Trading Fund OS, reported the disposition of their Repare common shares on January 28, 2026 in connection with a completed acquisition by XenoTherapeutics Inc. Under the arrangement, each common share was exchanged for $2.20 in cash plus one contingent value right for potential additional cash payments, and the BVF-related entities now report holding zero Repare shares after the transaction.
Repare Therapeutics Inc. has been acquired by XenoTherapeutics, Inc. through its subsidiary Xeno Acquisition Corp. Effective January 28, 2026, the buyer acquired all outstanding common shares.
Shareholders received $2.20 in cash per share plus one contingent value right per share for potential future cash payments. Following this transaction, the BVF funds and related reporting persons now report owning 0 shares, representing 0% of Repare’s outstanding common shares and have ceased to be beneficial owners of more than 5% of the company.
Repare Therapeutics director Carol Schafer has exited her position in the company through a cash-and-rights buyout. On January 28, 2026, she disposed of 8,000 common shares and had 37,941 stock options cancelled under an Arrangement Agreement involving XenoTherapeutics, Inc., Xeno Acquisition Corp., and XOMA Royalty Corporation.
Each common share was exchanged for $2.20 in cash plus one contingent value right (CVR). Each option was cancelled in return for $2.20 minus its exercise price per underlying share, plus one CVR per underlying share, effectively cashing out her remaining equity in connection with the acquisition of all Repare common shares.
Repare Therapeutics director Ann D. Rhoads reported the disposition of 4,000 common shares in connection with the company’s acquisition. On January 28, 2026, all of her shares were exchanged under an Arrangement Agreement with XenoTherapeutics, Inc., Xeno Acquisition Corp., and XOMA Royalty Corporation.
Each Repare share was converted into $2.20 in cash plus one non‑transferable contingent value right (CVR), and Rhoads now reports owning zero Repare common shares following the transaction.
Repare Therapeutics Inc. director Civik Thomas reported the disposition of 7,500 common shares on January 28, 2026, reducing his reported holdings to zero. The Form 4 lists the transaction code as "D" for a non-derivative disposition.
According to the Arrangement Agreement dated November 14, 2025 among Repare Therapeutics, XenoTherapeutics, Inc., Xeno Acquisition Corp., and XOMA Royalty Corporation, each Repare common share was acquired by the purchaser in exchange for $2.20 in cash per share plus one non-transferable contingent value right (CVR) per share.
Repare Therapeutics EVP and CFO Steve Forte reported the cancellation of his equity holdings following the company’s acquisition. On January 28, 2026, 56,786 common shares were disposed of, including shares from restricted stock units and the employee stock purchase plan, as part of an Arrangement Agreement.
Under this agreement, all issued and outstanding Repare common shares were acquired for $2.20 in cash per share plus one contingent value right (CVR). Several employee stock options to buy common shares, with various exercise prices and expirations, were also cancelled in exchange for $2.20 minus the option exercise price per underlying share plus one CVR per underlying share.
Repare Therapeutics SVP, Finance and CAO, Sandra Isabelle Barros Alves reported the cancellation of 31,622 common shares and two employee stock option grants on January 28, 2026 in connection with an Arrangement Agreement with XenoTherapeutics.
The common shares, including 18,800 underlying restricted stock units, and the options were exchanged for $2.20 in cash per share plus one non-transferable contingent value right (CVR) per share, with options receiving $2.20 less the applicable exercise price plus one CVR per underlying share. After these transactions, she reported holding zero common shares and zero derivative securities.
Pursuant to the Arrangement Agreement, Xeno Acquisition Corp. acquired all issued and outstanding Repare common shares on the same cash-and-CVR terms.
Repare Therapeutics Inc. filed a post-effective amendment to its existing shelf registration statement that had registered up to
This follows a completed transaction in which a subsidiary of XenoTherapeutics acquired all issued and outstanding Repare common shares for approximately